MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


IN BRIEF: NetScientific says PDS Biotech’s Versamune meets endpoints

ALN

NetScientific PLC - London-based deep tech and life sciences venture capital investor - Says its portfolio company, PDS Biotechnology Corp’s Versamune meets endpoints in a phase three trial for patients with HPV. NetScientific holds a 3.5% shareholding in PDS. Versamune is a T cell-activating platform that effectively stimulates a precise immune system response to a cancer-specific protein.

Current stock price: 62.39 pence, down 0.2%

12-month change: down 16%

Copyright 2024 Alliance News Ltd. All Rights Reserved.